Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 15/20 | 0.68 |
| ▸ | STK3 | Q13188 | 15/20 | 0.68 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.64 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | ABL2 | P42684 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438584 | 0.83 | LRRK2 (0.55) | STK4STK3LRRK2ABL1EGFR | |
| SCHEMBL8114068 | 0.83 | ADK (0.49) | STK4STK3LRRK2 | |
| SCHEMBL4353306 | 0.83 | LRRK2 (0.62) | STK4STK3LRRK2MAP4K4 | |
| SCHEMBL8107168 | 0.83 | LRRK2 (0.62) | STK4STK3LRRK2ABL1SRC | |
| SCHEMBL3787081 | 0.82 | SRC (0.50) | STK4STK3LRRK2BRAFTNNI3K | |
| SCHEMBL4787827 | 0.82 | DHFR (0.54) | STK4STK3LRRK2MAP4K4 | |
| SCHEMBL7021288 | 0.82 | LRRK2 (0.63) | STK4STK3LRRK2BRAFTNNI3K | |
| SCHEMBL31301542 | 0.81 | STK4 (1.00) | STK4STK3LRRK2 | |
| SCHEMBL7013879 | 0.80 | LRRK2 (0.65) | STK4STK3LRRK2ABL1EGFR | |
| SCHEMBL8112985 | 0.80 | CCNT1 (0.48) | STK4STK3LRRK2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009070328-A1 | MODULATORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) PATHWAY FOR USE IN THE TREATMENT OR PREVENTION OF SUBSTANCE ABUSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-04 | — | — | WO | disclosed |
| US-6051577-A | TYROSINE INHIBITORS; BONE DISORDERS | NOVARTIS AG (CH) | 2000-04-18 | — | — | US | disclosed |
| EP-0888353-A1 | NOVEL N-7-HETEROCYCLYL PYRROLO 2,3-D]PYRIDINES AND THEIR USE | Novartis AG (CH) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034895-A1 | NOVEL N-7-HETEROCYCLYL PYRROLO[2,3-D]PYRIDINES AND THEIR USE | NOVARTIS AG (CH) | 1997-09-25 | — | — | WO | disclosed |